Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - Greenridge Capital initiated coverage on MoneyHero Ltd. (NASDAQ:MNY) with a Buy rating and a $4.00 price target on Monday. The stock, currently trading at $1.05, has shown strong momentum with a 49% return over the past week, according to InvestingPro data.
The research firm cited significant revenue and profit potential as MoneyHero ramps up its high-margin insurance brokerage business and potentially expands into neighboring markets through acquisitions.
Greenridge Capital noted that management’s efforts over the past year to position the company for success appear to be overlooked by the market, but expects this perception to change as MoneyHero reports strong financial results in upcoming quarters.
The $4.00 target price is based on an enterprise value-to-revenue multiple of 1.25 times Greenridge’s 2026 revenue estimate of $118.0 million, and an enterprise value-to-EBITDA multiple of 10 times its 2026 adjusted EBITDA estimate of $12.6 million.
Both valuation metrics would place MoneyHero roughly in line with its peers, according to Greenridge Capital’s analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.